Who was studied, and how
Nine numbers in the abstract
Where each one falls
Where it lands on the map
9,154people with obesity, in this paper
The trial randomly assignedassigned by chance
liraglutide 3.0mg
placebo
Reported lower weight loss, no range given−8.00
randomisedThe trial randomly assignedassigned by chance
placebo
liraglutide 3.0mg
Reported lower weight loss, no range given−2.60
randomisedthe abstract, start to end
… to week 56) with liraglutide was 8.0±6.7% (2.6±6.9% with placebo); baseline creatinine with liraglutide was 76±15μmol/L and 74±15μmol/L after 56weeks (similar …
… weight loss with liraglutide was 5.9±5.5% (2.0±4.3% with placebo); baseline creatinine was 79±19μmol/L (77±16μmol/L, placebo) and 79±20μmol/L after 56weeks (76±15μmol/L, placebo).
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
Weight loss (baseline to week 56)liraglutide 3.0mg vs placebo
−8.00
Weight loss (baseline to week 56)placebo vs liraglutide 3.0mg
−2.60
Baseline creatinineliraglutide 3.0mg
76
Creatinine after 56 weeksliraglutide 3.0mg
74
Weight lossliraglutide 3.0mg vs placebo
−5.90
Weight lossplacebo vs liraglutide 3.0mg
−2.00
Baseline creatinineliraglutide 3.0mg
79
Baseline creatinineplacebo
77
Creatinine after 56 weeksplacebo
76
GLP-1 receptor agonistsBody weight & compositionKidney outcomes
1 / 4